ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.5117A>C (p.Asn1706Thr) (rs730881536)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000568700 SCV000668837 uncertain significance Hereditary cancer-predisposing syndrome 2017-08-03 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient evidence,In silico models in agreement (benign)
DNA and Cytogenetics Diagnostics Unit,Erasmus Medical Center RCV000607894 SCV000744463 likely benign Breast-ovarian cancer, familial 2 2015-09-21 criteria provided, single submitter clinical testing
Diagnostic Laboratory, Department of Genetics,University Medical Center Groningen RCV000607894 SCV000733261 likely benign Breast-ovarian cancer, familial 2 no assertion criteria provided clinical testing
GeneDx RCV000160082 SCV000210345 uncertain significance not provided 2017-06-01 criteria provided, single submitter clinical testing This variant is denoted BRCA2 c.5117A>C at the cDNA level, p.Asn1706Thr (N1706T) at the protein level, and results in the change of an Asparagine to a Threonine (AAT>ACT). Using alternate nomenclature, this variant would be defined as BRCA2 5345A>C. This variant has not, to our knowledge, been published in the literature as pathogenic or benign. BRCA2 Asn1706Thr was not observed in large population cohorts (NHLBI Exome Sequencing Project, The 1000 Genomes Consortium 2015, Lek 2016). Since Asparagine and Threonine share similar properties, this is considered a conservative amino acid substitution. BRCA2 Asn1706Thr occurs at a position that is not conserved and is located in the binding regions of RAD51 and POLH (Roy 2012, Buisson 2014). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether BRCA2 Asn1706Thr is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.